Quick Answer
Werewolf Therapeutics, Inc. reported R&D Expense of $44.83 million for fiscal year 2025.
Werewolf Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $44.83M | -20.6% |
| 2024 | $56.43M | +35.1% |
| 2023 | $41.78M | -22.3% |
| 2022 | $53.76M | +52.4% |
| 2021 | $35.27M | +111.9% |
| 2020 | $16.64M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $11.63M | -7.1% | -11.5% |
| June 30, 2025 | $13.14M | -13.9% | +0.2% |
| March 31, 2025 | $13.12M | +1.6% | +4.7% |
| September 30, 2024 | $12.53M | +15.6% | -18.0% |
| June 30, 2024 | $15.27M | +59.4% | +18.3% |
| March 31, 2024 | $12.91M | +10.3% | +19.1% |
| September 30, 2023 | $10.84M | -17.1% | +13.1% |
| June 30, 2023 | $9.58M | -31.0% | -18.1% |
- Werewolf Therapeutics, Inc. showed a decrease of -20.6% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Werewolf Therapeutics, Inc.’s r&d expense has grown by 169.4% (from $16.64 million to $44.83 million).
- The most recent figure is from Werewolf Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: